2026 Q2 - tulosraportti
48 päivää sitten
‧40 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 236 | - | - | ||
| 14 629 | - | - | ||
| 15 000 | - | - | ||
| 25 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenIsn't it a bit too quiet from the company? About PancreaSure, MediCare reimbursement and about how they reason about financing (and if/when a new share issue is needed). The website's news page is basically a blank slate.
About the silence. Yes you could well say that management is of the unusually quiet type. But then perhaps nothing particularly reportable is happening? Only management knows that. They do have email, in case pressing questions arise that you think they dare to answer. Anyway, it must be done via press releases so everyone gets hold of the most important news. Guesses: A. The actual reporting to New York will probably proceed as usual. It is more like some kind of laboratory certification if I have understood that part.. B. Medicare is going very slowly. They could have been more open with us there, I think. Probably a formality to submit an application when they think they have the pieces in place. This has been talked about as multi-step. They need some initial material to submit so that Medicare can evaluate them. Thereafter, there has been a whisper that they will give ongoing updates to Medicare. BUT, they haven't submitted the "start application" yet. C. The financing question is a painful one. And something they cannot reveal anything about until they are ready with a press release. Are they having partnership talks here and now? Nobody knows the answer publicly at least. D. Future outlook / Asia and such. Fluff / bluff / or real. Yes, what is being done there. Do not expect that there is capacity to seize the opportunity yet- ·17.9.There are probably only a few weeks left of the cash now? Then an answer regarding the financing question will be forced, otherwise the board of Immunovia AB can probably expect a no-confidence motion/vote.When the stock had a price of 20 and some øre. Then I set a maximum sell price. I got 37.80 in a so-called long-term order. The last order day for it is today 17. September. Talk about being hopeful with the price. Can forget about placing a hopeful price for a while?
- ·15.9."Congratulations", the stock has reached its lowest value. AI thought this about shorting such a low-valued stock: Conversation with Gemini You are spot on that its penny stock status is the main driver, but the restriction is actually enforced by broker risk management and share lending constraints, rather than a formal Nasdaq Stockholm minimum price rule. Here is why Nordnet lists IMMNOV as non-shortable: 1. No Share Lending Availability (Aktielån) To short a stock, a broker must first borrow physical shares from institutional holders (such as pension funds or large custodian accounts). Because Immunovia trades on Nasdaq First North Growth Market at sub-SEK levels (~0.14–0.16 SEK) with low institutional ownership, there simply isn't an institutional share-lending pool available for Nordnet to source borrow from. 2. Broker Liquidity & Margin Risk Brokers set internal risk tiers based on liquidity, market cap, and volatility. Extremely low-priced micro-caps have thin order books, making them prone to violent percentage spikes ("short squeezes"). To prevent catastrophic margin calls and clearing defaults, retail brokers like Nordnet set the collateral value (belåningsvärde) to 0% and automatically block short positions. 3. Exchange vs. Broker Rules Nasdaq Stockholm itself does not enforce a hard share price floor for short selling. Specialized institutional hedge funds can theoretically short micro-caps if they arrange over-the-counter (OTC) stock borrow directly with a custodian. The "No" you see on Nordnet's platform is strictly an internal broker restriction"
I don't quite understand what it is you are trying to investigate. The stock can be shorted, but not directly through Nordnet or Avanza. Short sellers can borrow shares from e.g. Avanza pension - ·15.9. · MuokattuIt now states 'No' regarding the stock being shortable. Wow. Is this some level for stocks that have reached certain low pennies? What do you others think if those who got cold feet after the emission in 2025 are out of the stock? Those who want out have had approximately a year to do so soon. Those who don't have ice in their veins are probably out of the stock a while ago. Wonderful to not have to see the short traders for a while. Without volume, also bad for short traders too?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |
2026 Q2 - tulosraportti
48 päivää sitten
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenIsn't it a bit too quiet from the company? About PancreaSure, MediCare reimbursement and about how they reason about financing (and if/when a new share issue is needed). The website's news page is basically a blank slate.About the silence. Yes you could well say that management is of the unusually quiet type. But then perhaps nothing particularly reportable is happening? Only management knows that. They do have email, in case pressing questions arise that you think they dare to answer. Anyway, it must be done via press releases so everyone gets hold of the most important news. Guesses: A. The actual reporting to New York will probably proceed as usual. It is more like some kind of laboratory certification if I have understood that part.. B. Medicare is going very slowly. They could have been more open with us there, I think. Probably a formality to submit an application when they think they have the pieces in place. This has been talked about as multi-step. They need some initial material to submit so that Medicare can evaluate them. Thereafter, there has been a whisper that they will give ongoing updates to Medicare. BUT, they haven't submitted the "start application" yet. C. The financing question is a painful one. And something they cannot reveal anything about until they are ready with a press release. Are they having partnership talks here and now? Nobody knows the answer publicly at least. D. Future outlook / Asia and such. Fluff / bluff / or real. Yes, what is being done there. Do not expect that there is capacity to seize the opportunity yet
- ·17.9.There are probably only a few weeks left of the cash now? Then an answer regarding the financing question will be forced, otherwise the board of Immunovia AB can probably expect a no-confidence motion/vote.When the stock had a price of 20 and some øre. Then I set a maximum sell price. I got 37.80 in a so-called long-term order. The last order day for it is today 17. September. Talk about being hopeful with the price. Can forget about placing a hopeful price for a while?
- ·15.9."Congratulations", the stock has reached its lowest value. AI thought this about shorting such a low-valued stock: Conversation with Gemini You are spot on that its penny stock status is the main driver, but the restriction is actually enforced by broker risk management and share lending constraints, rather than a formal Nasdaq Stockholm minimum price rule. Here is why Nordnet lists IMMNOV as non-shortable: 1. No Share Lending Availability (Aktielån) To short a stock, a broker must first borrow physical shares from institutional holders (such as pension funds or large custodian accounts). Because Immunovia trades on Nasdaq First North Growth Market at sub-SEK levels (~0.14–0.16 SEK) with low institutional ownership, there simply isn't an institutional share-lending pool available for Nordnet to source borrow from. 2. Broker Liquidity & Margin Risk Brokers set internal risk tiers based on liquidity, market cap, and volatility. Extremely low-priced micro-caps have thin order books, making them prone to violent percentage spikes ("short squeezes"). To prevent catastrophic margin calls and clearing defaults, retail brokers like Nordnet set the collateral value (belåningsvärde) to 0% and automatically block short positions. 3. Exchange vs. Broker Rules Nasdaq Stockholm itself does not enforce a hard share price floor for short selling. Specialized institutional hedge funds can theoretically short micro-caps if they arrange over-the-counter (OTC) stock borrow directly with a custodian. The "No" you see on Nordnet's platform is strictly an internal broker restriction"I don't quite understand what it is you are trying to investigate. The stock can be shorted, but not directly through Nordnet or Avanza. Short sellers can borrow shares from e.g. Avanza pension
- ·15.9. · MuokattuIt now states 'No' regarding the stock being shortable. Wow. Is this some level for stocks that have reached certain low pennies? What do you others think if those who got cold feet after the emission in 2025 are out of the stock? Those who want out have had approximately a year to do so soon. Those who don't have ice in their veins are probably out of the stock a while ago. Wonderful to not have to see the short traders for a while. Without volume, also bad for short traders too?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 236 | - | - | ||
| 14 629 | - | - | ||
| 15 000 | - | - | ||
| 25 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |
2026 Q2 - tulosraportti
48 päivää sitten
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenIsn't it a bit too quiet from the company? About PancreaSure, MediCare reimbursement and about how they reason about financing (and if/when a new share issue is needed). The website's news page is basically a blank slate.About the silence. Yes you could well say that management is of the unusually quiet type. But then perhaps nothing particularly reportable is happening? Only management knows that. They do have email, in case pressing questions arise that you think they dare to answer. Anyway, it must be done via press releases so everyone gets hold of the most important news. Guesses: A. The actual reporting to New York will probably proceed as usual. It is more like some kind of laboratory certification if I have understood that part.. B. Medicare is going very slowly. They could have been more open with us there, I think. Probably a formality to submit an application when they think they have the pieces in place. This has been talked about as multi-step. They need some initial material to submit so that Medicare can evaluate them. Thereafter, there has been a whisper that they will give ongoing updates to Medicare. BUT, they haven't submitted the "start application" yet. C. The financing question is a painful one. And something they cannot reveal anything about until they are ready with a press release. Are they having partnership talks here and now? Nobody knows the answer publicly at least. D. Future outlook / Asia and such. Fluff / bluff / or real. Yes, what is being done there. Do not expect that there is capacity to seize the opportunity yet
- ·17.9.There are probably only a few weeks left of the cash now? Then an answer regarding the financing question will be forced, otherwise the board of Immunovia AB can probably expect a no-confidence motion/vote.When the stock had a price of 20 and some øre. Then I set a maximum sell price. I got 37.80 in a so-called long-term order. The last order day for it is today 17. September. Talk about being hopeful with the price. Can forget about placing a hopeful price for a while?
- ·15.9."Congratulations", the stock has reached its lowest value. AI thought this about shorting such a low-valued stock: Conversation with Gemini You are spot on that its penny stock status is the main driver, but the restriction is actually enforced by broker risk management and share lending constraints, rather than a formal Nasdaq Stockholm minimum price rule. Here is why Nordnet lists IMMNOV as non-shortable: 1. No Share Lending Availability (Aktielån) To short a stock, a broker must first borrow physical shares from institutional holders (such as pension funds or large custodian accounts). Because Immunovia trades on Nasdaq First North Growth Market at sub-SEK levels (~0.14–0.16 SEK) with low institutional ownership, there simply isn't an institutional share-lending pool available for Nordnet to source borrow from. 2. Broker Liquidity & Margin Risk Brokers set internal risk tiers based on liquidity, market cap, and volatility. Extremely low-priced micro-caps have thin order books, making them prone to violent percentage spikes ("short squeezes"). To prevent catastrophic margin calls and clearing defaults, retail brokers like Nordnet set the collateral value (belåningsvärde) to 0% and automatically block short positions. 3. Exchange vs. Broker Rules Nasdaq Stockholm itself does not enforce a hard share price floor for short selling. Specialized institutional hedge funds can theoretically short micro-caps if they arrange over-the-counter (OTC) stock borrow directly with a custodian. The "No" you see on Nordnet's platform is strictly an internal broker restriction"I don't quite understand what it is you are trying to investigate. The stock can be shorted, but not directly through Nordnet or Avanza. Short sellers can borrow shares from e.g. Avanza pension
- ·15.9. · MuokattuIt now states 'No' regarding the stock being shortable. Wow. Is this some level for stocks that have reached certain low pennies? What do you others think if those who got cold feet after the emission in 2025 are out of the stock? Those who want out have had approximately a year to do so soon. Those who don't have ice in their veins are probably out of the stock a while ago. Wonderful to not have to see the short traders for a while. Without volume, also bad for short traders too?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 236 | - | - | ||
| 14 629 | - | - | ||
| 15 000 | - | - | ||
| 25 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 122 596 | 4 122 596 | 0 | 0 |